Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acelrx Pharmaceutica (ACRX)

Acelrx Pharmaceutica (ACRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,717
  • Shares Outstanding, K 90,478
  • Annual Sales, $ 2,290 K
  • Annual Income, $ -53,240 K
  • 60-Month Beta 1.48
  • Price/Sales 60.08
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ACRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.10
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.13
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3600 +7.35%
on 11/10/20
1.9600 -25.51%
on 11/05/20
-0.2500 (-14.62%)
since 10/30/20
3-Month
1.0500 +39.05%
on 09/11/20
2.1300 -31.46%
on 09/21/20
+0.2200 (+17.74%)
since 09/01/20
52-Week
0.7014 +108.16%
on 03/23/20
2.5000 -41.60%
on 12/11/19
-0.4000 (-21.51%)
since 11/29/19

Most Recent Stories

More News
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised...

ACRX : 1.4600 (-2.67%)
AcelRx Pharmaceuticals to Present at Credit Suisse 29th Annual Virtual Healthcare Conference

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised...

ACRX : 1.4600 (-2.67%)
AcelRx Pharmaceuticals (ACRX) Reports Q3 Loss, Misses Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -42.86% and -77.74%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

ACRX : 1.4600 (-2.67%)
AcelRx Pharmaceuticals Reports Third Quarter 2020 Financial Results

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically...

ACRX : 1.4600 (-2.67%)
AcelRx Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020...

ACRX : 1.4600 (-2.67%)
AcelRx to Host Third Quarter 2020 Financial Results Call and Webcast on Thursday, November 5, 2020

, /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close on . AcelRx management...

ACRX : 1.4600 (-2.67%)
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACRX : 1.4600 (-2.67%)
Aclaris (ACRS) Begins Phase II Study on Eczema Candidate

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

ACRX : 1.4600 (-2.67%)
ABBV : 104.04 (-0.52%)
ACRS : 3.52 (+5.39%)
AMRX : 4.05 (+2.53%)
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation

RedHill (RDHL) gets Orphan Drug status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

ACRX : 1.4600 (-2.67%)
RDHL : 8.59 (-2.83%)
EARS : 5.23 (+371.17%)
AMRX : 4.05 (+2.53%)
AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ACRX : 1.4600 (-2.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and...

See More

Key Turning Points

2nd Resistance Point 1.5667
1st Resistance Point 1.5133
Last Price 1.4600
1st Support Level 1.4333
2nd Support Level 1.4067

See More

52-Week High 2.5000
Fibonacci 61.8% 1.8129
Fibonacci 50% 1.6007
Last Price 1.4600
Fibonacci 38.2% 1.3885
52-Week Low 0.7014

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar